General MedicationsNASALGeneric
RHINOCORT
BUDESONIDE
Standard Dose
0.064MG/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview RHINOCORT is listed in Drugs@FDA under application 020746 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient BUDESONIDE Form and strength SPRAY, METERED;NASAL - 0.064MG/INH Sponsor KENVUE BRANDS Submission history Latest submission status date: 2017-05-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview RHINOCORT is listed in Drugs@FDA under application 020746 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BUDESONIDE Form and strength SPRAY, METERED;NASAL - 0.064MG/INH Sponsor KENVUE BRANDS Submission history Latest submission status date: 2017-05-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.